Use of etonogestrel subcutaneous implant in Sardinia, Italy: women’s compliance and satisfaction

References

• Guida M, Farris M, Aquino CI, et al. Nexplanon subdermal implant: assessment of sexual profile, metabolism, and bleeding in a cohort of italian women. Biomed Res Int. 2019;2019:3726957–3726956. doi: 10.1155/2019/3726957.
   PubMed Web of Science ®Google Scholar
• Menon K. Insertion and removal of nexplanon. BMJ Sex Reprod Health. 2021;47(1):70–70. doi: 10.1136/bmjsrh-2020-200635.
   PubMed Web of Science ®Google Scholar
• Mansour D. Nexplanon® what implanon® did next. J Fam Plann Reprod Health Care. 2010;36(4):187–189. doi: 10.1783/147118910793048629.
   PubMedGoogle Scholar
• Mansour D, Korver T, Marintcheva-Petrova M, et al. The effects of implanon® on menstrual bleeding patterns. Eur J Contracept Reprod Health Care. 2008;13(sup1):13–28. doi: 10.1080/13625180801959931.
   PubMed Web of Science ®Google Scholar
• Merck. Nexplanon (etonogestrel implant)—prescribing information. 2011. http://www.merck.com/product/usa/pi_circulars/n/Nexplanon®/Nexplanon®_pi.pdf
   Google Scholar
• Secura GM, Madden T, McNicholas C, et al. Provision of no-cost, long-acting contraception and teenage pregnancy. N Engl J Med. 2014;371(14):1316–1323. doi: 10.1056/NEJMoa1400506.
   PubMed Web of Science ®Google Scholar
• Harris ML, Egan N, Forder PM, et al. Contraceptive use among women through their later reproductive years: findings from an Australian prospective cohort study. PLoS One. 2021;16(8):e0255913. doi: 10.1371/journal.pone.0255913.
   PubMed Web of Science ®Google Scholar
• Darney P, Patel A, Rosen K, et al. Safety and efficacy of a single-rod etonogestrel implant (implanon): results from 11 international clinical trials. Fertil Steril. 2009;91(5):1646–1653. May doi: 10.1016/j.fertnstert.2008.02.140.
   PubMed Web of Science ®Google Scholar
• Bahamondes L, Brache V, Meirik O, et al. A 3-year multicentre randomized controlled trial of etonogestrel-and levonorgestrel-releasing contraceptive implants, with non- randomized matched copper-intrauterine device controls. Hum Reprod. 2015;30(11):2527–2538. doi: 10.1093/humrep/dev221.
   PubMed Web of Science ®Google Scholar
• Creinin MD, Kaunitz AM, Darney PD, et al. The US etonogestrel implant mandatory clinical training and active monitoring programs: 6-year experience. Contraception. 2017;95(2):205–210. doi: 10.1016/j.contraception.2016.07.012.
   PubMed Web of Science ®Google Scholar
• Birth control implant. J Midwifery Womens Health. 2018;63(4):503–504.
   PubMed Web of Science ®Google Scholar
• Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(3):1–103. doi: 10.15585/mmwr.rr6503a1.
   Web of Science ®Google Scholar
• Glisic M, Shahzad S, Tsoli S, et al. Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25(10):1042–1052. doi: 10.1177/2047487318774847.
   PubMed Web of Science ®Google Scholar
• Pharmacoeconomic report: etonogestrel Extended-Release subdermal implant (nexplanon): merck Canada inc: indication: for the prevention of pregnancy [internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020.
   Google Scholar
• Berlan ED, Richards MJ, Vieira CS, et al. Best practices for counseling adolescents about the etonogestrel implant. J Pediatr Adolesc Gynecol. 2020;33(5):448–454. Oct doi: 10.1016/j.jpag.2020.06.022.
   PubMed Web of Science ®Google Scholar
• Belsey EM, Machin D, d‘Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World health organization special programme of research, development and research training in human reproduction. Contraception. 1986;34(3):253–260. doi: 10.1016/0010-7824(86)90006-5.
   PubMed Web of Science ®Google Scholar
• Polis CB, Hussain R, Berry A. There might be blood: a scoping review on women’s responses to contraceptive-induced menstrual bleeding changes. Reprod Health. 2018;15(1):114. doi: 10.1186/s12978-018-0561-0.
   PubMed Web of Science ®Google Scholar
• Cohen R, Sheeder J, Teal SB. Predictors of discontinuation of long-acting reversible contraception Before 30 months of use by adolescents and young women. J Adolesc Health. 2019;65(2):295–302. doi: 10.1016/j.jadohealth.2019.02.020.
   PubMed Web of Science ®Google Scholar
• Mommers E, Blum GF, Gent TG, et al. Nexplanon, a radiopaque etonogestrel implant in combination with a next-generation applicator: 3-year results of a noncomparative multicenter trial. Am J Obstet Gynecol. 2012;207(5):388.e1-6–388.e6. Nov doi: 10.1016/j.ajog.2012.08.002.
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Di Cello A, et al. Nexplanon: the new implant for long-term contraception. A comprehensive descriptive review. Gynecol Endocrinol. 2012;28(9):710–721. Sep doi: 10.3109/09513590.2011.652247.
   PubMed Web of Science ®Google Scholar
• Matulich MC, Chen MJ, Schimmoeller NR, et al. Referral center experience with nonpalpable contraceptive implant removals. Obstet Gynecol. 2019;134(4):801–806. doi: 10.1097/AOG.0000000000003457.
   PubMed Web of Science ®Google Scholar
• Gwinnell E. Expulsion of implanon. J Fam Plann Reprod Health Care. 2007;33(3):211–211. doi: 10.1783/147118907781004877.
   PubMedGoogle Scholar
• Gillies R, Scougall P, Nicklin S. Etonogestrel implants—case studies of median nerve injury following removal. Aust Fam Physician. 2011;40:799–800.
   PubMed Web of Science ®Google Scholar
• Blumenthal PD, Gemzell-Danielsson K, Marintcheva-Petrova M. Tolerability and clinical safety of implanon. Eur J Contracept Reprod Health Care. 2008;(sup1):29–36. doi: 10.1080/13625180801960012.
   PubMedGoogle Scholar
• Modesto W, Dal Ava N, Monteiro I, et al. Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant. Arch Gynecol Obstet. 2015;292(6):1387–1391. doi: 10.1007/s00404-015-3784-0.
   PubMed Web of Science ®Google Scholar
• Romano ME, Braun-Courville DK. Assessing weight status in adolescent and young adult users of the etonogestrel contraceptive implant. J Pediatr Adolesc Gynecol. 2019;32(4):409–414. doi: 10.1016/j.jpag.2019.03.008.
   PubMed Web of Science ®Google Scholar
• Merck and Co i. highlights of prescribing information. 2019. www.fda.gov/medwatch
   Google Scholar
• Colditz GA, Willett WC, Stampfer MJ, et al. Patterns of weight change and their relation to diet in a cohort of healthy women. Am J Clin Nutr. 1990;51(6):1100–1105. doi: 10.1093/ajcn/51.6.1100.
   PubMed Web of Science ®Google Scholar
• Bahamondes L, Brache V, Ali M, et al. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement. Contraception. 2018;98(3):181–187. doi: 10.1016/j.contraception.2018.05.009.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Bateson D, McGeechan K, et al. A three-year comparative study of continuation rates, bleeding patterns and satisfaction in Australian women using a subdermal contraceptive implant or progestogen releasing-intrauterine system. Eur J Contracept Reprod Health Care. 2014;19(1):5–14. doi: 10.3109/13625187.2013.853034.
   PubMed Web of Science ®Google Scholar
• Worly BL, Gur TL, Schaffir J. The relationship between progestin hormonal contraception and depression: a systematic review. Contraception. 2018;97(6):478–489. doi: 10.1016/j.contraception.2018.01.010.
   PubMed Web of Science ®Google Scholar
• Peipert JF, Zhao Q, Allsworth JE, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011;117(5):1105–1113. Maydoi: 10.1097/AOG.0b013e31821188ad.
   PubMed Web of Science ®Google Scholar
• Funk S, Miller MM, Mishell DR, et al. Safety and efficacy of implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception. 2005;71(5):319–326. doi: 10.1016/j.contraception.2004.11.007.
   PubMed Web of Science ®Google Scholar
• Flores JB, Balderas ML, Bonilla MC, et al. Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant. Int J Gynaecol Obstet. 2005;90(3):228–233. Sep doi: 10.1016/j.ijgo.2005.06.007.
   PubMed Web of Science ®Google Scholar
• Wong RC, Bell RJ, Thunuguntla K, et al. Implanon users are less likely to be satisfied with their contraception after 6 months than IUD users. Contraception. 2009;80(5):452–456. doi: 10.1016/j.contraception.2009.03.021.
   PubMed Web of Science ®Google Scholar
• Rocca ML, Palumbo AR, Visconti F, et al. Safety and benefits of contraceptives implants: a systematic review. Pharmaceuticals (Basel). 2021;14(6):548. doi: 10.3390/ph14060548.
   PubMedGoogle Scholar
• Margatho D, Carvalho NM, Bahamondes L. Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months. Eur J Contracept Reprod Health Care. 2020;25(2):133–140. doi: 10.1080/13625187.2020.1725461.
   PubMed Web of Science ®Google Scholar